Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib

Published:2015-11-07 Issue:1 Volume:108 Page:
ISSN:1460-2105
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Carlisle Benjamin,Demko Nadine,Freeman Georgina,Hakala Amanda,MacKinnon Nathalie,Ramsay Tim,Hey Spencer,London Alex John,Kimmelman Jonathan

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/108/1/djv292/17986126/djv292.pdf

Reference133 articles.

1. Increasing value and reducing waste in research design, conduct, and analysis;Lancet,2014

2. How to increase value and reduce waste when research priorities are set;Lancet,2014

3. Life cycle of translational research for medical interventions;Science,2008

4. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US Food and Drug Administration: the class of 2008;JAMA Int Med,2014

5. Can the pharmaceutical industry reduce attrition rates?;Nat Rev Drug Discov,2004

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: Insights From Afatinib Clinical Trials Across Diverse Cancer Indications;Clinical Therapeutics;2024-06

2. Assessing patient risk, benefit, and outcomes in drug development: A decade of ramucirumab clinical trials;Cancer Medicine;2024-05

3. Assessing Patient Risk, Benefit, and Outcomes in Drug Development: A Decade of Lenvatinib Clinical Trials: A Systematic Review;Targeted Oncology;2024-03-11

4. Assessing patient risk, benefit and outcomes in drug development: an observational study of regorafenib clinical trials;BMJ Oncology;2024-03

5. Research encouraging off-label use of quetiapine: A systematic meta-epidemiological analysis;Clinical Trials;2024-01-29

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3